Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.